Stockscreener 앱 받기
1.74
0.00%
0.00
시간 외 거래:
1.66
-0.08
-4.60%
전일 마감가:
$1.74
열려 있는:
$1.715
하루 거래량:
19,298
Relative Volume:
0.78
시가총액:
$70.12M
수익:
$1.55M
순이익/손실:
$-27.51M
주가수익비율:
-2.0471
EPS:
-0.85
순현금흐름:
$-50.09M
1주 성능:
+7.41%
1개월 성능:
-21.38%
6개월 성능:
-36.50%
1년 성능:
+91.21%
1일 변동 폭
$1.69
$1.7485
1주일 범위
$1.62
$1.8551
52주 변동 폭
$0.7777
$4.00
Beyondspring Inc Stock (BYSI) Company Profile
BYSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BYSI | 1.74 | 70.12M | 1.55M | -27.51M | -50.09M | -0.85 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-12-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | 개시 | Robert W. Baird | Outperform |
| 2021-08-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | 개시 | BofA Securities | Buy |
| 2020-12-29 | 개시 | Evercore ISI | Outperform |
| 2020-02-07 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | Nomura | Buy |
| 2019-12-03 | 개시 | William Blair | Outperform |
| 2019-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-30 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-10-25 | 재확인 | Maxim Group | Buy |
모두보기
Beyondspring Inc 주식(BYSI)의 최신 뉴스
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
BeyondSpring Presents Updated Efficacy Results from a Phase - GlobeNewswire
BeyondSpring's Lung Cancer Drug Shows 89% Disease Control Rate in Phase 2 Trial | BYSI Stock News - StockTitan
ROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsight - The Malaysian Reserve
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Neutropenia Treatment Market to hit USD 20.8 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
BioWorld Cancer Index continues to decline amid broader market gains - BioWorld Online
Biotech Stocks Facing FDA Decision In November - RTTNews
BYSI (BeyondSpring) Cash From Discontinued Investing Activi - GuruFocus.com
Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Renaissance Technologies LLC Increases Stock Holdings in Mesa Air Group, Inc. (NASDAQ:MESA) - Defense World
CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight - PR Newswire UK
Caspase 8 Market Analysis, Trends, Growth, Research And Forecast 2030 - La Funcion mx
G-CSF (Granulocyte Colony Stimulating Factors) Market Size, Analysis, Trends, Overview And Forecast To 2033 - WhaTech
BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus.com
BYSI: BeyondSpring Inc. Stock Surges 7.27% Amid Market Fluctuati - GuruFocus.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Acadian Asset Management LLC Has $34,000 Stock Position in BeyondSpring Inc. (NASDAQ:BYSI) - Defense World
Chemotherapy Induced Neutropenia Market Size is Set for Rapid - openPR
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC - MSN
BeyondSpring reports safer NSCLC therapy option - Investing.com India
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - StockTitan
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - StockTitan
BeyondSpring presented interim Phase 2 data on 303 Study - TipRanks
BeyondSpring Presents Efficacy/Safety Results from a Phase - GlobeNewswire
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase - GlobeNewswire
BeyondSpring (NASDAQ:BYSI) Trading Up 3.3% - MarketBeat
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type... - Markets Insider
BeyondSpring announces Dublin-3 final phase 3 efficacy data - TipRanks
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - GlobeNewswire
BeyondSpring Announces Oral Presentation at the 2024 World - GlobeNewswire
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - StockTitan
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? - Yahoo Finance
BeyondSpring Inc. Reports Mid-Year Financials - TipRanks
Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - The Malaysian Reserve
BeyondSpring (NASDAQ:BYSI) Stock Price Down 0.5% - MarketBeat
BYSI (BeyondSpring) EV-to-Revenue : 40.75 (As of Aug. 19, 2024) - GuruFocus.com
BYSI (BeyondSpring) GF Value Rank : 10 (As of Aug. 18, 2024) - GuruFocus.com
BYSI (BeyondSpring) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023) - GuruFocus.com
Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products - Scrip
BioWorld Cancer Index drops overall; Blueprint, TG catapulted in Q1 - BioWorld Online
Chemotherapy Induced Neutropenia Market Forecasted to Surge - openPR
SEED Therapeutics (SEED) Enters into Strategic Research - GlobeNewswire
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - StockTitan
Global Cancer Supportive Care Drugs Market to Cross 17 Billion Mark by 2030| DelveInsight - 新浪香港
Drugs for Traveler’s Diarrhea Industry to Witness an Outstanding Growth by 2030 |GSK, Salix Pharmaceuticals, Chiesi Farm – Moose Gazette - Moose Gazette
O Shaughnessy Asset Management LLC Buys 21,202 Shares of Haleon plc (NYSE:HLN) - Defense World
Cencora (NYSE:COR) Releases FY 2024 Earnings Guidance - Defense World
Beyondspring Inc (BYSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):